CT-868 is an experimental "biased dual GLP-1 and GIP receptor modulator that exhibits no arrestin coupling or receptor internalization at either receptor". It is developed by Carmot Therapeutics for diabetes and obesity.[1][2]
Chakravarthy, Manu; Hernandez, Moises; Elliott, Michael; Macias, Alejandra; Hansen, Stig K.; Hompesch, Marcus (20 June 2023). "774-P: Weight-Independent Effects of CT-868, a Signaling Biased Dual GLP-1/GIP Receptor Modulator, on Glucose Homeostasis in Overweight and Obese Adults with Type 2 Diabetes". Diabetes. 72 (Supplement_1). doi:10.2337/db23-774-P. S2CID259219222.